AI Precision for Cardiovascular Health

AI Precision for Cardiovascular Health

We're building a solution to stop the world’s leading killer, one patient at a time

We're building a solution to stop the world’s leading killer, one patient at a time

Vascentis combines AI, biology, and advanced imaging with standard risk factors to reshape cardiovascular care. By guiding clinicians to the right therapy for each patient, we aim to reduce risks, unlock efficiencies, and improve outcomes worldwide.

Vascentis combines AI, biology, and advanced imaging with standard risk factors to reshape cardiovascular care. By guiding clinicians to the right therapy for each patient, we aim to reduce risks, unlock efficiencies, and improve outcomes worldwide.

Vascentis combines AI, biology, and advanced imaging with standard risk factors to reshape cardiovascular care. By guiding clinicians to the right therapy for each patient, we aim to reduce risks, unlock efficiencies, and improve outcomes worldwide.

Get In Touch

Get In Touch

Get In Touch

The Problem
The Problem
The Problem

Cardiovascular Disease: The #1 Killer

Cardiovascular Desease: the #1 Killer

Cardiovascular disease — including heart attacks, ischemic strokes, and other related conditions — remains the leading cause of death and disability globally.

Cardiovascular disease — including heart attacks, ischemic strokes, and other related conditions — remains the leading cause of death and disability globally.

0M+
0M+
0M+

Deaths in 2022 for cardiovascular disease

$0B
$0B
$0B

Direct care + productivity loss, 2018–2019

0M
0M
0M

People had some form of CVD between 2017-2020

0%
0%
0%

Of CVD deaths due to coronary heart disease

Our Solution
Our Solution

An AI-Driven Decision Support Platform

We turn complex cardiovascular data into clear, practical guidance, helping clinicians prescribe with confidence.

Built for Clinical Use

Designed to meet clinical standards and evaluate partient eligibility for advanced therapies.

Designed to meet clinical standards and evaluate partient eligibility for advanced therapies.

Actionable Insights

Provides clear recommendations and targeted test suggestions to confirm the best treatment path.

Provides clear recommendations and targeted test suggestions to confirm the best treatment path.

Our Solution
Our Solution

An AI-Driven Decision Support Platform

Our Approach
Our Approach
Our Approach

Biology-Aware AI for Tailored Therapeutics

Biology-Aware AI for Tailored Therapeutics

By combining patient data with biologically informed models, we can specifically target specific drugs to specific patients.

By combining patient data with biologically informed models, we can specifically target specific drugs to specific patients.

Before

Generalized guidelines

Generalized guidelines

Population averages

Risk scores

Broad categories

Population averages

Risk scores

Broad categories

Same drug for all patients

Underutilization of most effective agents

Underutilization of most effective agents

Due to inability to target responders

With Vascentis

'N of 1' systems pharmacology

'N of 1' systems pharmacology

N of 1 systems

pharmacology

Intensive

lipid lowering

Anti-

glycemic

Anti-

inflammatory

Emerging

Emerging

Use of otherwise underutilized drugs with high value in specific patients

Use of otherwise underutilized drugs with high value in specific patients

Use of otherwise underutilized drugs with high value in specific patients

Value For Patients
Value For Patients
Value For Patients

Care That Evolves With The Patient

Care That Evolves With The Patient

This clinical decision support system employs reinforcement learning based on observed patient outcomes following its recommendations.

By continuously integrating real-world clinical results, the system adapts its guidance for individual patients and improves its decision-making performance across the broader population.

This clinical decision support system employs reinforcement learning based on observed patient outcomes following its recommendations.

By continuously integrating real-world clinical results, the system adapts its guidance for individual patients and improves its decision-making performance across the broader population.

Occupancy

Before

Before

High readmission

High readmission

Outcomes

Adverse events

Condition returns

Follow-ups

Occupancy

With Vascentis

With Vascentis

Safe discharge

and no returns

Safe discharge and no returns

Outcomes

Better recovery

Normal routines

Healthy life

Value For Providers
Value For Providers
Value For Providers

Better Care, Fewer Returns

Better Care, Fewer Returns

With precise care, providers and hospitals can lower readmissions and adverse events, driving better outcomes, stronger performance, and sizable gains to the bottom line.

With precise care, providers and hospitals can lower readmissions and adverse events, driving better outcomes, stronger performance, and sizable gains to the bottom line.

Avoid financial penalties

Avoid financial penalties

Avoid financial penalties

Unlock hospital capacity

Unlock hospital capacity

Unlock hospital capacity

Hit quality targets

Hit quality targets

Hit quality targets

Patients recover at home

Patients recover at home

Patients recover at home

Value For Payers
Value For Payers
Value For Payers

Unlocking Billions in Efficiency Gains

Unlocking Billions in Efficiency Gains

Cardiovascular healthcare is massive, yet under-optimized. By enabling smarter decisions, we can save lives while cutting expenses wasted on mis-prescriptions, redundant testing, and underused therapies.

Cardiovascular healthcare is massive, yet under-optimized. By enabling smarter decisions, we can save lives while cutting expenses wasted on mis-prescriptions, redundant testing, and underused therapies.

Invest strategically

Direct funds where they deliver savings

Direct funds where they deliver savings

Act proactively

Stop reacting to costs after they occur.

Stop reacting to costs after they occur.

Focus resources

Avoid spreading resources thinly

Avoid spreading resources thinly

Profits

Profits

Inefficiencies waiting to be optimized

Inefficiencies waiting to be optimized

Cardiovascular healthcare is massive, yet under-optimized. By enabling smarter decisions, we can save lives while cutting expenses wasted on mis-prescriptions, redundant testing, and underused therapies.

Focus resources

Avoid spreading resources thinly

Invest strategically

Direct funds where they deliver savings

Act proactively

Stop reacting to costs after they occur.

Why This Team?
Why This Team?
Why This Team?

Biology + AI + FDA wins

Biology + AI + FDA wins

A rare combination of expertise in biology and AI, experienced in both pharmaceutical and device products requiring substantial FDA approval.

A rare combination of expertise in biology and AI, experienced in both pharmaceutical and device products requiring substantial FDA approval.

Andrew Buckler, PhD

Andrew Buckler, PhD

Andrew Buckler, PhD

Founder and Chief Executive Officer

Executive, scientist, and serial entrepreneur.

Multidisciplinarian at the intersection of cardiovascular biology, AI/ML, and systems pharmacology.

Founder of Elucid, $200M+ funded to commercialize advanced CVD phenotyping, including vulnerable plaque and vasodilative capacity.

>70 peer reviewed publications and > 50 issued patents.

Dr. Gregg W. Stone, MD, FACC, FSCAI

Dr. Gregg W. Stone, MD, FACC, FSCAI

Dr. Gregg W. Stone, MD, FACC, FSCAI

Founding Partner and Head of MAB

Cardiologist and Dir of Acad Affairs for Mt Sinai Heart and Prof. Med, Icahn School of Medicine.

PI for 150+ trials, 3000+ pubs, 1000s invited lectures.

H-index of 206, top 0.01% of cited on Web of Science.

Expert on drug-eluting stents and bioresorbable scaffolds, acute myocardial infarction and vulnerable plaque.

Dr. Brajesh Lal, MD, MBBS, FACS

Dr. Brajesh Lal, MD, MBBS, FACS

Chief of Vascular Surgery, UMMC, Mayo, and VA. Co-chair of CREST-2.

Dr. Ulf Hedin, MD PhD

Dr. Ulf Hedin, MD PhD

Prof Vascular Surgery and Molecular Medicine, KI (Stockholm). PI of BiKE.

Dr. David Erlinge, MD PhD

Dr. David Erlinge, MD PhD

Head of Cardiology, Skane U (Lund) and Leader of CV trials including SCAPIS.

Dr. Patrick Serruys, MD PhD

Dr. Patrick Serruys, MD PhD

Prof Interventional Cardiology and Innovation, NUI Galway.

Clint Miller, PhD

Clint Miller, PhD

Functional genomics of complex cardiovascular diseases at Stanford/UVA.

Ian Kemp MBA MSF

Ian Kemp MBA MSF

Founding Partner and Chief Business Officer.

Let’s shape the future of cardiovascular health

Let’s shape the future of cardiovascular health

Let’s shape the future of cardiovascular health

Advanced therapies exist, pharmacogenomics is maturing, and AI is finally capable of integrating biology and data at scale.

It's time to put these tools to work.

© 2025 Vascentis.